A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Public ClinicalTrials.gov record NCT07024784. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Study identification
- NCT ID
- NCT07024784
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 377 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 30, 2025 (Actual)
- Primary completion
- Jan 2028 (Estimated)
- Completion
- Feb 2028 (Estimated)
- Last update posted
- Oct 1, 2026
2025 – 2028
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Start Los Angeles /ID# 281533 | Los Angeles | California | 90025 | Recruiting |
| University of Colorado Hospital- Aurora /ID# 278232 | Aurora | Colorado | 80045-2527 | Recruiting |
| University Of Minnesota /ID# 277850 | Minneapolis | Minnesota | 55455 | Recruiting |
| Holy Name Medical Center /ID# 279017 | Teaneck | New Jersey | 07666 | Recruiting |
| SUNY Upstate Medical University - Syracuse /ID# 277305 | Syracuse | New York | 13210 | Recruiting |
| University of Cincinnati Medical Center. /ID# 278925 | Cincinnati | Ohio | 45219 | Recruiting |
| University Hospitals Cleveland Medical Center /ID# 279601 | Cleveland | Ohio | 44106 | Recruiting |
| OU Health - Stephenson Cancer Center /ID# 277656 | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Providence Portland Medical Center /ID# 277727 | Portland | Oregon | 97213 | Recruiting |
| Women & Infants Hospital /ID# 277930 | Providence | Rhode Island | 02905 | Recruiting |
| SCRI Oncology Partners /ID# 279733 | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology-Austin North /ID# 279958 | Austin | Texas | 78758 | Recruiting |
| Next Virginia /ID# 279684 | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07024784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07024784 live on ClinicalTrials.gov.